Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura.
about
Repeated courses of rituximab in chronic ITP: Three different regimens.Consensus Paper-ICIS Expert Meeting Basel 2009 treatment milestones in immune thrombocytopeniaLow-dose rituximab combined with short-term glucocorticoids up-regulates Treg cell levels in patients with immune thrombocytopenia.Low-dose rituximab therapy for refractory thrombocytopenia in patients with systemic lupus erythematosus--a prospective pilot study.Efficacy of rituximab in immune thrombocytopenic purpura: a retrospective survey.Therapeutic options for immune-mediated thrombocytopenia.Corticosteroids and rituximab as adjunctive treatments for thrombotic thrombocytopenic purpura.Efficacy of rituximab in primary immune thrombocytopenia: an analysis of adult pretreated patients from everyday hematological practice.Low-dose rituximab for the treatment of acute thrombotic thrombocytopenic purpura: report of four cases.High response rate to low-dose rituximab plus high-dose dexamethasone as frontline therapy in adult patients with primary immune thrombocytopenia.Efficacy and safety of rituximab given at 1,000 mg on days 1 and 15 compared to the standard regimen to treat adult immune thrombocytopenia.Cost effectiveness of romiplostim for the treatment of chronic immune thrombocytopenia in IrelandLow-dose rituximab in the treatment of acquired haemophilia.Involvement of NLRP3 inflammasome in rituximab-induced interstitial lung disease: a case report.A multicenter randomized open-label study of rituximab plus rhTPO vs rituximab in corticosteroid-resistant or relapsed ITP.A novel triple therapy for ITP using high-dose dexamethasone, low-dose rituximab, and cyclosporine (TT4).Phytochemicals as potential therapeutics for thrombocytopenia.More about low-dose rituximab and plasma exchange as front-line therapy for patients with thrombotic thrombocytopenic purpura.Efficacy and Safety of Rituximab for Refractory and Relapsing Thrombotic Thrombocytopenic Purpura: A Cohort of 10 Cases.Effectiveness of subcutaneous low-dose alemtuzumab and rituximab combination therapy for steroid-resistant chronic graft-versus-host diseaseLong-term remission induced by low-dose rituximab for relapsed and refractory thrombotic thrombocytopenic purpura: A report of two cases.Immune thrombocytopenia successfully treated with eltrombopag following multiple therapies including romiplostim.Slow responses to standard dose rituximab in immune thrombocytopenic purpura.Slow responses to standard dose rituximab in immune thrombocytopenic purpura. Author reply.Is a reduced intensity treatment with Rituximab effective in acquired haemophilia A?A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia.Single, very low rituximab doses in healthy volunteers - a pilot and a randomized trial: implications for dosing and biosimilarity testing.Low Dose Rituximab in Chronic ITP: Still an Option in Resource Limited Settings.
P2860
Q33386117-BAFA7800-C09C-4E73-B1AC-7AABFD715EA9Q33389001-C910E3DB-7C97-4317-9881-17D06A38C628Q33393434-77CD2BA2-7AB8-4A5B-A9A4-F8C02BDF63DDQ33395310-CFB6945A-5A8D-423F-8111-D2DAF9ABE279Q33395961-15165E0C-499B-4872-AAC5-B5CCC31AA897Q33399601-4598C78E-115A-47F9-B01F-2361E86C3EF8Q33400195-CB9ECAC4-6DF8-4034-A0D0-BFE3CA708746Q33404032-39018656-8513-43DF-9956-757D920BAEEAQ33406040-9547C273-8A8E-41A8-808E-493A677F1D15Q33406310-C0703827-383E-40D1-AE49-403B27BF54FBQ33408621-BEEE7A32-2039-4E5F-9B2D-CA703EBB798CQ33409109-4991BC0E-8A4E-4F1F-A3BB-9901C6C08E3CQ33413790-00F0AA4F-35EC-4594-9AF6-87D707EDD12BQ33417132-20F73ED0-9FF7-49A3-8E6E-B003DC8F1893Q33419712-D3CEE103-5C0F-4BE5-800D-543C3F73E46FQ33422782-1A556909-4C28-4C2E-B4B4-FF6A49A44CF6Q33425035-47BC4CF5-87DE-4E24-ADD3-7941C967184DQ33430243-8A5E7CBE-43DF-4968-B510-926353809FF7Q35672416-D1B1667D-062B-4726-9E19-BE4E891FF7A3Q35930604-73ECEA1D-EF31-4C3E-98BE-4127DF10680AQ36336555-ED597D49-F592-4D16-B064-DC979A8A089CQ42430722-2F1803A0-9838-461B-AA41-36688FF2E505Q43171567-4E59029E-149F-4B56-9B5A-1CF79550D16FQ45746603-C5389DA2-C02D-461E-95EF-EA39DC51B812Q45867964-F022D9CB-C909-4606-B7A4-E0AB9E779DB9Q47690234-BEB74F4B-59FB-4D31-B687-CA4FD91E5D13Q48276545-1142DAB2-050E-4CDB-B21D-074BD606686BQ50092881-864E55D4-5CDA-4F62-9E2F-7CD8993E15B5
P2860
Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura.
description
2008 nî lūn-bûn
@nan
2008 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Lower dose rituximab is active ...... thic thrombocytopenic purpura.
@ast
Lower dose rituximab is active ...... thic thrombocytopenic purpura.
@en
type
label
Lower dose rituximab is active ...... thic thrombocytopenic purpura.
@ast
Lower dose rituximab is active ...... thic thrombocytopenic purpura.
@en
prefLabel
Lower dose rituximab is active ...... thic thrombocytopenic purpura.
@ast
Lower dose rituximab is active ...... thic thrombocytopenic purpura.
@en
P2093
P356
P1433
P1476
Lower dose rituximab is active ...... thic thrombocytopenic purpura.
@en
P2093
Felicetto Ferrara
Franca Soldano
Francesca Patriarca
Francesco Zaja
Luciana Marin
Margherita Cavallin
Maria Antonietta Avanzini
Maria Teresa Pirrotta
Mario Regazzi
Marta Lisa Battista
P304
P356
10.3324/HAEMATOL.12206
P577
2008-04-09T00:00:00Z